Use of the Dyskinesia Impairment Scale in non-ambulatory dyskinetic cerebral palsy

Helga Haberfehlner*, Laura A. Bonouvrie, Karin Boeschoten, Sabine Fleuren, Elegast Monbaliu, Jules G. Becher, R. Jeroen Vermeulen, Annemieke I. Buizer

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

1 Citation (Web of Science)

Abstract

Aim To assess the responsiveness, concurrent validity, and feasibility of the Dyskinesia Impairment Scale (DIS) in non-ambulatory patients with dyskinetic cerebral palsy (CP). Method The study is a secondary analysis of data collected in the IDYS trial, a randomized controlled trial on the effects of intrathecal baclofen (ITB). The DIS and Barry-Albright Dystonia Scale (BADS) were conducted at baseline and after 3 months of ITB or placebo treatment. Responsiveness was assessed by comparing the effect sizes and correlation of change after treatment between the DIS and BADS. Concurrent validity was evaluated by assessing the correlations between scales. Feasibility was evaluated for each DIS item by the number of participants who successfully accomplished the item. Results Thirty-three non-ambulatory patients (9 females, 24 males) with dyskinetic CP (ITB-treated: n=17, mean [SD] age: 14y 1mo [4y 1mo]; placebo-treated: n=16, mean [SD] age: 14y 7mo [4y]) were included in the study. The effect sizes for BADS and DIS were similar in The ITB-treated group (-0.29 and -0.22 respectively). Changes after treatment on the DIS dystonia subscale correlated with changes on the BADS (r=0.64; p

Original languageEnglish
Pages (from-to)494-499
Number of pages6
JournalDevelopmental Medicine and Child Neurology
Volume62
Issue number4
Early online date29 Nov 2019
DOIs
Publication statusPublished - Apr 2020

Keywords

  • INTRATHECAL BACLOFEN
  • MEASURE DYSTONIA
  • CHILDREN
  • RELIABILITY
  • VALIDITY
  • CHOREOATHETOSIS
  • INSTRUMENT

Cite this